标题：百令胶囊联合信必可对中重度慢性阻塞性肺疾病患者肺功能及氧化应激的影响

      作者：孙颖    (宝鸡市中医医院呼吸科，陕西 宝鸡 721000)

      卷次： 2017年28卷24期

      【摘要】 目的 探讨百令胶囊联合信必可治疗中重度慢性阻塞性肺疾病(COPD)的疗效及对患者肺功能和氧化应激的影响。方法 选择2015年1月至2016年10月宝鸡市中医医院收治的COPD患者118例为研究对象，采用随机数表法将其分为观察组和对照组，每组59例，对照组给予信必可都保吸入治疗，观察组采用信必可都保吸入联合百令胶囊治疗，两组疗程均为12周，比较两组治疗后的临床疗效，以及治疗前、治疗12周后的肺功能指标及氧化应激指标水平。结果 观察组患者的临床治疗总有效率为96.61% (57/59)，明显高于对照组的83.05%，差异有统计学意义(P<0.05)。观察组患者的治疗12周后的第1秒用力呼吸容积(FEV1)、FEV1预测值、FEV1占用力呼气肺活量百分比(FEV1/FVC)、超氧化物歧化酶(SOD)和总抗氧化能力(T-AOC)分别为(1.48±0.27) L、(51.32±7.46)%、(64.37±7.62)%、(98.62±7.74) KU/L和(13.26±3.11) KU/L，明显高于对照组的(1.23±0.34) L、(44.42±7.52)%、(57.29±8.24)%、(71.38±7.67) KU/L和(9.47±1.85) KU/L，差异均有统计学意义(P<0.05)。观察组患者治疗12周后的丙二醛(MDA)为(2.23±0.67) mmol/L，明显低于对照组的(3.74±0.78) mmol/L，差异有统计学意义(P<0.05)。结论 百令胶囊联合信必可治疗中重度COPD可明显提高临床疗效，改善患者肺功能及氧化应激水平。
      【关键词】 慢性阻塞性肺疾病；百令胶囊；信必可；肺功能；氧化应激
      【中图分类号】 R563 【文献标识码】 A 【文章编号】 1003—6350（2017）24—3980—03

Influence of Bailing Capsule combined with symbicort on lung function and oxidative stress of patients withmoderate to severe chronic obstructive pulmonary disease.
SUN Ying. Department of Respiratory, Baoji Hospital ofTraditional Chinese Medicine, Baoji 721000, Shaanxi, CHINA
【Abstract】 Objective To explore the curative effect of Bailing Capsule combined with symbicort in the treat-ment of moderate to severe chronic obstructive pulmonary disease (COPD) and its effect on lung function and oxidativestress. Methods A total of 118 patients with COPD who were treated in our hospital from January 2015 to October2016 were selected as the research objects. They were divided into observation group (59 cases) and control group (59cases) according to random number table. The control group was treated by symbicort, and the observation group appliedBailing Capsule combined with symbicort. The period of treatment was 12 weeks. The clinical effects of two groupswere compared. The lung function and the level of oxidative stress were compared between the two groups before treat-ment and 12 weeks after treatment. Results The clinical total effective rate of observation group was 96.61% (57/59),which was significantly higher than 83.05% (49/59) in the control group (P<0.05). The first second forced expiratory vol-ume (FEV1), FEV1 predictive value, FEV1 accounted for the percentage of forced expiratory vital capacity (FEV1/FVC), superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) in the observation group were (1.48±0.27) L,(51.32±7.46)%, (64.37±7.62)%, (98.62±7.74) KU/L and (13.26±3.11) KU/L respectively after 12 weeks treatment, sig-nificantly higher than that (1.23±0.34) L, (44.42±7.52)%, (57.29±8.24)%, (71.38±7.67) KU/L and (9.47±1.85) KU/L inthe control group (P<0.05). The malondialdehyde (MDA) in the observation group was (2.23±0.67) mmol/L 12 weeks af-ter treatment, which was significantly lower than (3.74±0.78) mmol/L in the control group (P<0.05). Conclusion TheBailing Capsule combined with symbicort in the treatment for moderate or severe COPD can improve the clinical cura-tive effect obviously, and improve the patient's lung function and oxidative stress level.
      【Key words】 Chronic obstructive pulmonary disease; Bailing Capsule; Symbicort; Lung function; Oxidative stress·论 著·doi:10.3969/j.issn.1003-6350.2017.24.007